271 related articles for article (PubMed ID: 8210256)
1. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
[TBL] [Abstract][Full Text] [Related]
2. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Ohno R; Yoshida Y; Oguro M; Ogawa M; Sakai Y; Furue H; Ariyoshi Y; Saito H; Masaoka T; Kimura I
Gan To Kagaku Ryoho; 1994 Jan; 21(1):75-82. PubMed ID: 8291918
[TBL] [Abstract][Full Text] [Related]
3. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Ohno R; Okada K; Masaoka T; Kuramoto A; Arima T; Yoshida Y; Ariyoshi H; Ichimaru M; Sakai Y; Oguro M
J Clin Oncol; 1990 Nov; 8(11):1907-12. PubMed ID: 2230878
[TBL] [Abstract][Full Text] [Related]
4. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
[TBL] [Abstract][Full Text] [Related]
5. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
[TBL] [Abstract][Full Text] [Related]
7. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
9. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
[TBL] [Abstract][Full Text] [Related]
10. [A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Taguchi T; Tominaga T; Ogawa M; Ishida T; Morimoto K; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1017-24. PubMed ID: 8210251
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.
Tsuda H; Takatsuki K; Ohno R; Masaoka T; Okada K; Shirakawa S; Ohashi Y; Ota K
Br J Cancer; 1994 Oct; 70(4):771-4. PubMed ID: 7917938
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Takagi T; Saotome T
Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
[TBL] [Abstract][Full Text] [Related]
16. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Saotome T; Takagi T; Sakai C; Kumagai K; Tamaru J
Ann Oncol; 2000 Jan; 11(1):115-6. PubMed ID: 10690400
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
19. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
